Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)
AMANDA OLGA MÜLLER(Kantonsspital St. Gallen), Roger von Moos(Kantonsspital Graubünden), Julian Schardt(Kantonsspital St. Gallen), Sacha I. Rothschild(University Hospital of Basel), Daniel Rauch(Washington University in St. Louis), Silke Gillessen(Institute of Oncology Research), Andrea Fuhrer(Swiss Group For Clinical Cancer Research), Michael Schwitter(Kantonsspital St. Gallen), Ursula Hasler-Strub(Kantonsspital Graubünden), T Wehrhahn(Kantonsspital Aarau), Hanne Hawle(Swiss Group For Clinical Cancer Research), Khalil Zaman, Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Roman Inauen(University of St.Gallen), Olivia Pagani(Swiss Group For Clinical Cancer Research), BC Pestalozzi(Kantonsspital St. Gallen), Alexandre Bodmer(Kantonsspital St. Gallen), Priska Bützberger(Kantonsspital Baden), Răzvan Popescu(Hirslanden Klinik Aarau), AJ Templeton(Kantonsspital St. Gallen), Daniel Betticher, Markus Borner(University of Bern), Corinne Schär(Kantonsspital St. Gallen)
Cited by 2
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k